The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Updates from the Phase II ANIMATE trial of nivolumab in R/R cHL
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares updates from the Phase II ANIMATE trial (NCT03337919), which is investigating the use of positron emission tomography (PET) response-adapted treatment using nivolumab in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Notably, there have been no relapses among those who proceeded to stem cell transplantation (SCT). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Roche, Beigene, Astra Zeneca, Abbvie, Sobi, Kite / Gilead, BMS, Pfizer, SecuraBio.
